TransMedics Group (NASDAQ:TMDX) Upgraded by Zacks Research to Strong-Buy Rating

TransMedics Group (NASDAQ:TMDX) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Other analysts have also issued reports about the company. Oppenheimer lifted their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 17th. Stifel Nicolaus initiated coverage on TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 price objective for the company. Evercore ISI began coverage on TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective on the stock. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, August 30th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $125.40.

TransMedics Group Stock Performance

TransMedics Group stock opened at $112.20 on Monday. The stock’s 50 day moving average price is $116.57 and its 200 day moving average price is $109.63. TransMedics Group has a one year low of $55.00 and a one year high of $155.99. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm has a market capitalization of $3.82 billion, a PE ratio of 58.14 and a beta of 2.18.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to the consensus estimate of $146.64 million. During the same period in the prior year, the firm earned $0.35 earnings per share. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that TransMedics Group will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On TransMedics Group

Large investors have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in shares of TransMedics Group by 0.8% in the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock worth $1,285,000 after purchasing an additional 80 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after buying an additional 100 shares during the last quarter. Smartleaf Asset Management LLC increased its position in TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after buying an additional 108 shares during the period. Ameritas Investment Partners Inc. lifted its stake in TransMedics Group by 4.4% in the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company’s stock valued at $455,000 after buying an additional 142 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in TransMedics Group by 1.0% in the second quarter. Franklin Resources Inc. now owns 14,842 shares of the company’s stock valued at $1,989,000 after buying an additional 148 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.